Yet, response to monotherapy with Crizotinib may be more heterogenous, as suggested by another study comprising eight EGFRm+ NSCLC patients, who acquired MET amplification during EGFR-TKI treatment and exhibited mPFS of only 1.4 months [31]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.